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Abstract Mutations in the voltage-gated Cav2.1 P/Q-type
calcium channel (CACNA1A) can cause a wide spectrum of
phenotypes, including the episodic ataxia type 2. Beside the
growing number of descriptions of novel CACNA1A muta-
tions with episodic ataxia type 2 phenotype; there are only
rare reports on interictal oculomotor signs other than nys-
tagmus. We describe a novel CACNA1A mutation and an
unclassified CACNA1A in-frame variant in a Swiss family
presenting as the episodic ataxia type 2 phenotype associ-
ated with reduced saccade velocity. In this case series
interictal clinical examination showed only minimal neu-
rological findings as mild limb ataxia and nystagmus, but
most interestingly saccade analysis of all three affected
individuals demonstrated reduced mean saccade velocity.
Genetic testing of CACNA1A revealed a de novo frame-shift
mutation (c.2691dupC/p.Thyr898Leufs*170) in the index
patient in addition to an unclassified in-frame variant
(c.6657_6659dupCCA/p.His2220dup) segregating in all
three affected individuals. The de novo frame-shift CAC-
NA1A mutation and the unclassified in-frame CACNA1A
variant were associated with the episodic ataxia type 2
phenotype and reduced mean saccade velocity, which sug-
gests involvement of brainstem or neural pathways con-
necting brainstem and the cerebellum in this disease.
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Introduction
The episodic ataxia type 2 (EA2) is an autosomal domi-
nant inherited disorder usually presenting with recurrent
episodes of vertigo and ataxia lasting for hours to days.
Attacks may be triggered by alcohol, fever, and physical
or emotional stress. Symptoms range from pure ataxia to
other neurological symptoms such as migraine-like head-
ache, fluctuating limb weakness, dystonia (e.g., torticollis),
and epileptic seizures [1, 2]. Clinical onset is typically in
the first two decades of life. The EA2 is caused by
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mutations in the CACNA1A gene on chromosome 19p13
which encodes the pore forming a1 subunit of voltage-
gated Cav2.1 P/Q-type calcium channels which are pre-
dominantly expressed on cerebellar Purkinje cells [3]. The
EA2 is allelic with familial hemiplegic migraine type 1
(FHM1) and CAG-repeat expansions in The CACNA1A
cause spinocerebellar ataxia type 6 (SCA6) [4]. In addi-
tion to the clinical overlap of FHM1, SCA6 and EA2, a
wide range of EA2 phenotypes have been associated with
mutations in CACNA1A.
Different ictal and interictal neuro-ophthalmologic
findings are associated with EA2 [1, 3, 5]. Patients may
present with spontaneous nystagmus during an acute
episode. Interictally, up to 90 % of EA2 patients show
nystagmus such as gaze-evoked and downbeat nystag-
mus [1, 6]. Beside the growing number of descriptions
of novel CACNA1A mutations with EA2 phenotype,
there are only rare reports on interictal oculomotor signs
other than nystagmus [7–10]. The current study
describes a novel CACNA1A mutation and an unclassi-
fied in-frame variant in three members of a Swiss family
presenting as EA2 phenotype with interictal reduced
saccade velocity.
Subjects and methods
Four members of a Caucasian family in Switzerland were
examined in the University Hospital of Bern. Due to the
typical history, we suspected EA2 in the 22-year-old
female index patient, her mother and one of her two sib-
lings. Genetic testing for CACNA1A mutation, clinical and
neurophysiologic studies were performed after obtaining
written informed consent.
Mutation analysis
Screening of all coding areas as well as exon–intron
boundaries of the CACNA1A gene have been performed by
conventional bidirectional Sanger sequencing. Deletions
and duplications have been excluded by Multiplex Liga-
tion-dependent Probe Amplifications (MRC-Holland
P279).
Detected variants were compared to a control cohort of
180 alleles sequenced similarly under equal conditions as
well as 10,308 alleles from the exome variant server (http://
evs.gs.washington.edu/EVS) comprising 7,120 alleles of
European and 3,188 alleles of African ancestry.
Phenotype analysis
For the quantification of interictal cerebellar deficit, we
used the International Cooperative Ataxia Rating Scale
(ICARS) [11]. Clinical subtests included evaluation of
posture and gait, kinetic functions, speech and oculomotor
functions.
Saccade analysis
Quantitative testing of saccades was performed on all three
mutation carriers. Visually guided horizontal saccades
were recorded binocularly with a sampling frequency of
300 Hz using the infrared-based video EyeBrain Tracker
(EBT). After the presentation of a central fixation point
for a variable duration (2,400–3,600 ms), the lateral target
with an amplitude of 22 to the left or right (20 repetitions
to each side) appeared for 1,000 ms. Mean and peak
velocity of adducting (add) and abducting (abd) saccades
were separately calculated for right (RE) and left eye (LE)
and compared to a normative database (data of 63 healthy
control subjects aged 18–80 years). The significance
between proband and the control group was tested
according to Crawford and Howell [12]. A p value
of \0.05 was accepted as statistically significant.
Results
Proband 1 (index patient)
A 22-year-old woman was referred to the neuro-ophthal-
mologic unit in June 2011 with migraine and unusual visual
symptoms. She reported a 3-year history of recurrent acute
episodes with vertigo, slurred speech, ataxia, severe gait
impairment and oscillopsia provoked by emotional stress or
by alcohol consumption. She experienced two attacks per
month at an average each lasting for several hours. The
interictal clinical investigation revealed mild limb ataxia,
primary position upbeat- and gaze-evoked nystagmus and
saccadic smooth pursuit (see online video) corresponding
to an ICARS score of 7. Suppression of the vestibulo-ocular
reflex was incomplete. Interictal saccade analysis by ocu-
lography revealed a reduction of mean saccade velocity
with preserved peak velocity and significant slowing of
adducting saccades consistent with internuclear ophthal-
moplegia (INO) (Table 1; Fig. 1 and online Figure).
Compared to the control group, the reduction of mean
horizontal saccade velocity was significant (p values: RE
add \ 0.001, RE abd = 0.001, LE add = 0.001, LE
abd = 0.002). The EEG and EMG examination was normal
without signs of epileptic activity or neuromuscular trans-
mission failure. The MRI of the brain showed slight atro-
phy of the cerebellar vermis. The laboratory screening
including serologic and metabolic analysis was unremark-
able. Genetic testing revealed a de novo frame-shift CAC-
NA1A mutation (c.2691dupC/p.Thyr898Leufs*170) located
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in the loop between protein domains II and III. Addition-
ally, we detected an unclassified in-frame variant
(c.6657_6659dupCCA/p.His2220dup). After the introduc-
tion of an acetazolamide treatment (500 mg per day) the
patient experienced only three short attacks during the
follow up period of 1 year.
Proband 2 (brother)
The 20-year-old brother of the index patient experienced
rare and short (some minutes) lasting vertigo attacks
during physical exercise. These episodes were associated
with a strange feeling in the head, tingling in the mouth
and unsteadiness. Nevertheless, these attacks were not
hindering sport activities. Around the age of five, his
mother had observed recurrent episodes of torticollis with
eye deviation. Furthermore, according to the available
medical history there have been several episodes of dis-
turbed consciousness of unknown etiology. In clinical
examination, the proband showed hypometric saccades
corresponding to an ICARS score of 1. Compared to the
control group, the reduction of mean saccade velocity
was significant (p values: RE add = 0.006, RE
abd = 0.02, LE add = 0.021, LE abd = 0.004). Genetic
testing revealed that the patient also carries the unclas-
sified in-frame CACNA1A variant (c.6657_6659dupCCA/
p.His2220dup) but not the frame-shift mutation
c.2691dupC.
Proband 3 (mother)
The 55-year-old mother of the index patient reported
recurrent spells of disturbances in consciousness during
febrile episodes in infancy. Clinical investigation revealed
minor ataxia of the upper extremities and hypometric,
horizontally slow saccades corresponding to an ICARS
score of 6. Saccade analysis showed significantly reduced
mean saccade velocities for the right eye but not for left
eye analysis (p values: RE add = 0.048, RE abd = 0.007,
LE add = 0.053, LE abd = 0.055). Genetic testing did not
identify the frame-shift mutation but the unclassified in-
frame CACNA1A variant (c.6657_6659dupCCA/
p.His2220dup).
Proband 4 (father)
The 56-year-old father of the index patient was unaffected.
The clinical investigation was normal and genetic testing
did neither identify the frame-shift nor the in-frame CAC-
NA1A variant.
Discussion
We describe a Swiss family presenting as EA2 phenotype
with interictal reduced mean saccade velocity and the
segregation of two novel CACNA1A variants. One of
these variants is a frame-shift mutation (c.2691dupC/
p.Thyr898Leufs*170) leading to a subsequent stop codon
and presumably nonsense-mediated mRNA decay. Similar
to other frame-shift mutations leading to EA2 the muta-
tion c.2691dupC is predicted to cause a loss of channel
function [13]. It is likely that c.2691dupC is a de novo
mutation as it is not present in the parental DNA. In
addition to the frame-shifting mutation c.2691dupC, the
index patient carries an unclassified in-frame variant
(c.6657_6659dupCCA/p.His2220dup). Both variants were
Fig. 1 Interictal saccade analysis. Bar graphs showing mean saccade
velocity (?SEM). Beside reduction of mean saccade velocity there is
a more pronounced deceleration of adducting saccades (consistent
with INO) in the index patient (proband 1). Gray shaded area
indicating 90 %-confidence interval. RE right eye, LE left eye
Table 1 Clinical and paraclinical EA2 proband characteristics
Proband no. 1 (patient) 2 (brother) 3 (mother)
Age (year) 22 20 55
p.Thyr898Leufs*170 Y N N
p.His2220dup Y Y Y
Clinical features
Ataxia Y N Y
Nystagmus Y N N
VOR-suppression A I I
Saccadic smooth pursuit Y N N
Hypometric saccades Y Y Y
SWJ N N N
Ocular motor studies
Slow saccade velocity Y Y Y
INO Y N N
NA not ascertained, Y yes, N no, I intact, A abnormal, SWJ square
wave jerks, INO internuclear ophthalmoplegia, VOR vestibulo-ocular
reflex
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absent in 180 control alleles and in 10,308 alleles of the
exome variant server. Up to this point it remains unclear
whether the de novo mutation occurred on the same allele
already carrying the in-frame variant or in a compound
heterozygous state. The functional impact of this histidine
duplication in the C-terminus is unclear without func-
tional studies. Interestingly, all three suspected EA2 cases
of our family were found to be carriers of this variant.
The segregation of p.His2220dup with an EA2 phenotype
with interictal reduction of mean saccade velocity and
mild ataxia in the family might point toward a pathogenic
role of this variant.
The common interictal oculomotor finding in EA2 is
primary position upbeat nystagmus [1, 6]. In this report
we identified interictal reduction of mean saccade velocity
and clinically hypometric saccades most pronounced in
the index patient. An INO was additionally identified in
the index patient. In the literature, general saccade
slowing in EA2 was described only in three subjects of
one EA2 kindred [8, 9], whereas Baloh et al. [10] found
no slowing of peak saccade velocities. These prior find-
ings and our results cannot be attributed to a pure cere-
bellar pathology [14]. Furthermore, the INO in the index
patient is consistent with involvement of the brainstem
[7]. The slowing of saccade velocity in our EA2 subjects
suggests an additional disorder of neurotransmitter release
of neuron subpopulations in brainstem pathways of sac-
cades [3, 14]. It is widely accepted that specific CAC-
NA1A mutations do not strictly predict EA2 phenotype,
but a subtle interictal affection of saccades may be a more
common early finding in EA2 probably in analogy to
oculomotor findings in presymptomatic SCA6 subjects,
which also show reduced saccade velocity [15]. Since
approximately only one third of suspected EA2 cases
could be associated with a detectable CACNA1A mutation
[16, 17], oculography may be an additional helpful
diagnostic tool, especially in cases with minimal interictal
neurologic findings.
Conclusions
The identified de novo frame-shift CACNA1A mutation
and the unclassified in-frame CACNA1A variant were
associated with episodic ataxia type 2 phenotype and
reduced mean saccade velocity, which suggests involve-
ment of brainstem or neural pathways connecting brain-
stem and cerebellum in this disease. Future studies will
have to address the question whether saccade abnormal-
ities are associated with individual genotypes or represent
an early manifestation of general oculomotor dysfunction
in EA2.
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